A5026208455- Renal Transplantation Outcomes and Treatments
- Organ Transplantation Techniques and Outcomes
- Pharmacological Effects and Toxicity Studies
- Neurological Complications and Syndromes
- Organ Donation and Transplantation
- Transplantation: Methods and Outcomes
- Polyomavirus and related diseases
- Viral-associated cancers and disorders
- Renal and Vascular Pathologies
- Renal Diseases and Glomerulopathies
- Cytomegalovirus and herpesvirus research
- Liver Disease and Transplantation
- Pregnancy and Medication Impact
- Organ and Tissue Transplantation Research
- Metabolism and Genetic Disorders
- Oral and gingival health research
- Complement system in diseases
- Pneumocystis jirovecii pneumonia detection and treatment
- Monoclonal and Polyclonal Antibodies Research
- Blood groups and transfusion
- HIV/AIDS drug development and treatment
- Hematopoietic Stem Cell Transplantation
- Pancreatic function and diabetes
- Mycobacterium research and diagnosis
- Clinical Nutrition and Gastroenterology
Astellas Pharma (United States)
2005-2021
Providence College
2021
Northwestern University
2017-2020
Genomics (United Kingdom)
2020
Mansfield University
2017-2020
Center for Global Development
2010-2015
University of Cincinnati
1998-2008
Astellas Pharma (China)
2005-2008
University of Cincinnati Medical Center
1996-2005
Tulane University
2005
In Brief Objective: To compare outcomes with early corticosteroid withdrawal (CSWD) and chronic low dose therapy (CCS). Summary Background Data: Final, 5-year results from the first randomized, double-blind, placebo-controlled trial of CSWD (at 7 days posttransplant) are presented. Methods: Adult recipients deceased living donor kidney transplants without delayed graft function were randomized to receive prednisone (5 mg/d after 6 months or CSWD. Blinding was maintained for 5 years. This...
There are few comparisons of antibody induction therapy allowing early glucocorticoid withdrawal in renal-transplant recipients. The purpose the present study was to compare involving alemtuzumab with most commonly used regimens patient populations at either high immunologic risk or low risk.
In the general population Merkel's cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer. More than 600 cases have been reported. MCC seems to be common in transplant recipients, with 41 being reported Cincinnati Transplant Tumor Registry, and another 11 literature. population, it a disease of older adults, only 5% occurring below age 50 years. patients, mean at diagnosis was 53 (range 33-78) years, 29% recipients were <50 years old. The tumor appeared from 5 286 (mean 91.5)...
Thymoglobulin, a rabbit anti-human thymocyte globulin, was compared with Atgam, horse globulin for the treatment of acute rejection after renal transplantation.A multicenter, double-blind, randomized trial enrollment stratification based on standardized histology (Banff grading) conducted. Subjects received 7-14 days Thymoglobulin (1.5 mg/kg/ day) or Atgam (15 mg/kg/day). The primary end point reversal (return serum creatinine level to below day 0 baseline value).A total 163 patients were...
Introduction. Short-term and long-term results of renal transplantation have improved over the past 15 years. However, there has been no change in prevalence recurrent de novo diseases. A retrospective study was initiated through Renal Allograft Disease Registry, to evaluate impact diseases after transplantation. Materials Methods. From October 1987 December 1996, a total 4913 transplants were performed on adults at Medical College Wisconsin, University Cincinnati, California San Francisco,...
Transplant recipients are at increased risk of malignancy; however, the influence transplantation on cancer outcomes has not been rigorously defined. The purpose this study was to examine individual cancers.De novo nonsmall cell lung cancer, colon breast prostate bladder renal (RCC), and malignant melanoma data in 635 adult (>18 years age) transplant (from Israel Penn International Tumor Registry) were compared with from 1,282,984 adults general population Surveillance, Epidemiology, End...
The incidence of cancers after renal transplantation is significantly higher than in populations that have not undergone transplantation. authors report a group transplant patients from the University Cincinnati who had cancer develop; focus on patients' clinical course.Since 1968, 876 transplantations been performed for variety causes end stage disease. Charts neoplasms were reviewed.Forty-four epithelial skin cancers, and 36 nonskin or melanoma. No correlations could be established between...
A review of 693 renal transplant recipients revealed 77 (11%) in whom persistent, heavy proteinuria (greater than 2 g/24 hr) developed. Renal histology was available all patients. Twenty-one patients had received kidneys from living-related donors, the remaining 56 cadaveric donors. The cause these as follows: glomerulopathy (30), allograft glomerulonephritis (22), chronic rejection (21), vein thrombosis (2), diabetic glomerulosclerosis (1), and hypertensive nephrosclerosis (1). Of 22 who...
New-onset diabetes after transplantation (NODAT) is an important complication following kidney transplantation. Data from the 5-year early steroid withdrawal double-blind randomized trial were analyzed to determine if avoidance reduced NODAT risk. Incidence, timing and risk factors for evaluated using eight definitions. By American Diabetes Association definition, 36.3% of patients on chronic corticosteroids (CCS) 35.9% corticosteroid (CSWD) diagnosed with by 5 years. The definition...
In a phase III, open-label, comparative, noninferiority study, 638 subjects receiving de novo kidney transplants were randomized to one of three treatment arms: tacrolimus extended-release (Astagraf XL) qd, (Prograf) bid, or cyclosporine (CsA) bid. All received basiliximab induction, mycophenolate mofetil, and corticosteroids. Safety efficacy follow-up data through 4 years are reported.Evaluations included patient graft survival, study drug discontinuations, laboratory values including renal...
In view of the superior T-cell depletion and prolonged half-life thymoglobulin, we initiated a protocol to administer thymoglobulin intermittently based on peripheral blood CD3+ lymphocyte counts.In this prospective study, 41 consecutive high-risk cadaver transplant recipients (panel reactive antibody level >30%, repeat recipients, simultaneous pancreas kidney or after cold-ischemia time, donor hypotension, non-heart-beating donors) who received induction therapy were included. The first...
Background. Posttransplant diabetes mellitus (PTDM), associated with the use of immunosuppressants, occurs at varying rates in kidney transplant recipients. Methods. Five centers conducted a retrospective review 435 recipients completing least 6 months follow-up to determine risk factors, incidence, and management strategies for posttransplant glucose intolerance. A distinction was made between hyperglycemia diabetes. Results. The incidence PTDM found be 4.9%. Among tacrolimus-treated...
In an era of organ shortage, the use expanded or marginal donors has been attempted to increase transplantation rates and diminish waiting list mortality. One strategy is organs from patients with a history active central nervous system (CNS) tumor.Sixty-two recipients were identified as CNS malignancy. Patient demographics, donor tumor management, incidence transmission, patient survival examined.Of recovered transplanted astrocytoma, 14 associated at least one risk factor including...
Tacrolimus extended-release (XL) is a once-daily formulation recently developed to reduce the frequency of dosing for patients currently using twice-a-day tacrolimus (TAC). As reported previously, 67 kidney transplant recipients were safely converted (1:1 mg basis, total daily dose) from TAC XL in morning and maintained on an am regimen same therapeutic monitoring patient care techniques employed with TAC. The 2-year postconversion (100%) graft (98.5%) survival, incidence biopsy-confirmed...